Thera-SAbDab

TAFASITAMAB

> Structural Summary

Therapeutic	Tafasitamab
Target	CD19
Heavy Chain	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS
Light Chain	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-III
Estimated Status (June '19)	Active
Recorded Developmental Technology	MorphoSys HuCAL Phage Display;XmAb Engineering Technology
INN Year Proposed	2018
INN Year Recommended	2019
Companies Involved	MorphoSys, The Ohio State University Comprehensive Cancer Center, Xencor
Conditions Approved	na
Conditions Active	Diffuse large B cell lymphoma, Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]